The Department of Homeland Security is targeting immigrants who have sought assistance from food stamps, welfare, Medicaid, Medicare Part D, and housing vouchers; there is wide variation among ketamine clinics, including the screening of patients, dosages, frequency of infusions, and coordination with patients’ mental health providers; public health advocates are upset over a decision by the Trump administration to divert nearly $200 million from health programs to fund the detention of unaccompanied migrant children who crossed into the country illegally.
The Department of Homeland Security is targeting immigrants who have sought assistance from the Supplemental Nutrition Assistance Program (food stamps), Temporary Assistance for Needy Families (welfare), Medicaid, Medicare Part D, and housing vouchers, Politico reported. But in a departure from earlier leaked drafts, the proposed rule won't target immigrants who have received subsidized health insurance under the Affordable Care Act or the Children's Health Insurance Program. The move is an effort to drastically cut all immigration, both legal and illegal, but health advocates fear it will restrict children's access to food and healthcare. Under the rule, immigrants can be denied so-called "lawful permanent residency" if they have received certain government benefits or if the government suspects they may do so in the future.
A STAT News investigation found wide inconsistencies among ketamine clinics, including the screening of patients, dosages, frequency of infusions, and coordination with patients’ mental health providers. A number of clinics stray from recommendations issued last year by the American Psychiatric Association, STAT said. Ketamine, used in anesthesia and illegally as a club drug, is being promoted for the treatment of depression, based on a number of small studies.
Public health advocates are upset over a decision by the Trump administration to divert nearly $200 million from health programs to fund the detention of unaccompanied migrant children who crossed into the country illegally. The Hill reported that the health programs targeted in the transfer include $16.7 million from the CDC, $9.8 million from Medicare and Medicaid program operations, and $87.3 million overall from the National Institutes of Health. The money should be spent on cancer research, vaccines for rare diseases, and other health priorities, advocates said.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More